

0001178913-25-0003496-K TRINITY BIOTECH PLC 2025020620250206090033090035090035 0 0001178913-25-000349 6-K 3 20250206 20250206 20250206 TRINITY BIOTECH PLC 0000888721 2835 000000000 L2 1231 6-K 34 000-22320 25595633 IDA BUSINESS PARK, BRAY, CO WICKLOW IRELAND DUBLIN IRELAND L2 18 01135312955111 3 ROCK ROAD SANDYFORD INDUSTRIAL ESTATES DUBLIN IRELAND L2 18 6-K 1 zk2532668.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C.Â 20549 F O R MÂ 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland Â (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F â~Â Â Â Form 40-F â~Â Â Â Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):Â Â Â Â Â Â Â Â Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):Â Â Â Â Â Â Â Â Â Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes â~Â Â Â No â~ If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-Â Â Â Â Â Â Â Â Â Â Â Â Â Â This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Registration Statements on Form F-3 (File Nos. 333-239701, 333-264992 and 333-267160). Â EXPLANATORY NOTE On February 6, 2025, the Company issued a press release announcing new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance for its next-generation continuous glucose monitoring (CGM) system. EXHIBIT INDEX Exhibit Â Â Â 99.1 Trinity Biotech announces findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance for its next-generation continuous glucose monitoring (CGM) system. Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â TRINITY BIOTECH PLC Â Â Â Trinity Biotech plc Â Â Â (Registrant) Â Â Â Â Â Â By: /s/ Louise Tallon Â Â Â Louise Tallon Â Â Â Chief Financial Officer Â Date: February 6, 2025 EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Trinity Biotech plc Gary Keating, Ph.D (353)-1-2769800 RedChip Companies Inc.Â Â Â Â Â Â Â Â Â Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com LifeSci Partners, LLCÂ Â Â Eric Ribner (1)-646-751-4363 investorrelations@trinitybiotech.com Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial Trinity Biotechâ€™s patented technology represents a paradigm shift in the global CGM market, projected to exceed \$20 billion by 2029 DUBLIN, Ireland (February 6, 2025) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance for its next-generation continuous glucose monitoring (CGM) system. The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than 50% improvement in Mean Absolute Difference (MAD) with Trinity Biotechâ€™s redesigned CGM sensor compared to the previously marketed Waveform product. The first 24 hours of CGM wear have been a persistent weak spot across the industry, with sensor accuracy often fluctuating due to the bodyâ€™s natural response to insertion. These advancements promise to address a key pain point for users, as inconsistent glucose readings on the first day of wear have historically led to user frustration and safety concerns. Builds On Other Breakthrough Results from Latest Pre-Pivotal Trial Trinity Biotechâ€™s latest pre-pivotal trial involved 30 diabetic participants, primarily individuals with Type 1 diabetes, each of whom wore multiple sensors over a 15-day period. As previously reported, the trial evaluated modifications made by Trinityâ€™s R&D team to technology acquired from Waveform Technologies, Inc. that enhance sensor design and performance, which in addition the significant first-day performance improvement, also yielded the following exceptional results: â€¢ Superior Signal Quality: Significant improvements in signal clarity compared to previously released Waveform CGM sensors. â€¢ Enhanced Reliability Post-Insertion: Sensor performance immediately after placement demonstrated markedly improved consistency, reducing variability for users. â€¢ Breakthrough Accuracy: A 25-30% improvement in the key accuracy metricâ€”mean absolute relative difference (MARD)â€”over earlier Waveform CGM sensors. â€¢ Industry-Standard Low-Glucose Precision: Accuracy for low blood sugar readings (measured by mean absolute difference, or MAD) is now aligned with industry benchmarks, a critical achievement for hypoglycemia management. Revolutionizing CGM Accessibility and Performance Trinity Biotechâ€™s redesigned ergonomic modular CGM system is designed with affordability, accuracy, and sustainability in mind. The deviceâ€™s reusable and rechargeable components are designed to reduce costs for users while minimizing environmental impact. The Trinity CGM represents a paradigm shift in the market, and promises to make continuous glucose monitoring more accessible to millions of individuals who have previously been unable to afford it. Next Steps: Advancing Toward Commercialization These latest findings reinforce Trinityâ€™s confidence in delivering a high-performance, calibration-free CGM system that meets the FDAâ€™s iCGM standards. The Company remains on track for regulatory submissions in Europe in 2025, followed by a U.S. FDA filing in 2026, with commercialization efforts targeting both diabetes patients and broader health-conscious consumers.Â Building on the success of its latest trial, Trinity now plans to begin further pre-pivotal clinical trials in Q1 2025 on additional device enhancements. To stay updated on Trinity Biotechâ€™s CGM developments, visit <https://cgm.trinitybiotech.com>. Forward-Looking Statements This release includes statements that constitute â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995 (the â€œReform Actâ€), including but not limited to statements related to Trinity Biotechâ€™s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms â€œmay,â€ â€œbelieves,â€ â€œprojects,â€ â€œexpects,â€ â€œanticipates,â€ or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech potential excess inventory levels and inventory imbalances at the Companyâ€™s distributors, losses or system failures with respect to Trinity Biotechâ€™s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating

results, dependence on suppliers, the market acceptance of Trinity Biotechâ€™s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotechâ€™s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Trinity Biotechâ€™s annual report on Form 20-F for the fiscal year ended December 31, 2023 and Trinity Biotechâ€™s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements. About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

GRAPHIC 3



begin

644




image1.jpg

M_JC_X 02D9)1@ ! 0\$ 8 ! @ # _VP! \$ \$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!

0\$! 0\$! 0\$! 0\$! 0\$! 0' _MVP!# 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!

0' _P 1" \$\$ \P# 2(A\$! Q\$! _0 M^P 04! 0\$! 0\$ \$" P0%!@<("OH+ _0 M1 @\$# P(\$ P4% M! 0 %] 0(#

0!1(A,4&\$&\$U%A!R)Q%#*!D:\$((T*QP152T? D,V)R@>D*

M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*C!6FIZBJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-

76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_0 'P\$ P\$! 0\$! M 0\$! 0 \$" P0%!@<("OH+ _0 M1\$ @\$"! 0#! <%! 0 0)W \$"

M Q\$\$!2\$Q!A)!40=A<1,B,H\$(%\$*1H;'!"2,S4O 58G+1"A8D-.\$E\1<8&1HF M)R@I*C4V-S@Y.D-

\$149'2\$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ>H.\$

MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM::WN+FZPL/\$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ _JH # ,!

(1 Q\$ /P# ^ BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****

"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH

**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H HHMH **** "BBB@

HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****

"BBB@ HHHH ***0 MG'.">>PS^!.S^~0/KTS0 M%(3@\$X'/OY_ +_/KTJ(3*3C#=NV>IQV)\ 7TS@ MX-;7Z+6 0:3>R;MY?

UW)J* <^OX@C]#S10(**0G RGR_S_\$W#3KJNJTK?3U36Z=F<[0" \$QR M>XZ\$?)Y>.NC1[2.,\$8STX!Y"/.(SM(VX R=LN

M #C!&(2I'7H>V.N<1,%8!P #G:"!P..0/W:XS[G;' Q,9IRY(J[F]-E:RLK- M/7?6Z>EK*)AI_%

[14J>MWHK7M;WGMHKVM>Z:TZ7\$&U0, 8[#&/J, #'Z]![B MG51AN4^X#G!?.EEW+GMM\$1'WLC!

((P>"0:ME\#)I:Q[!S^@OD_P"31*45*46] M4]59Z.JMK::L2M9_(Q4U"Dl.;JO7^M1Z^?)?UKYZ;H****8!1110 4444 %%%%

!1110 M4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

!1 M110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

M% !1110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

%%%%

!1110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

!1110 4444 %%%%

'.#CKV_SD?S'U'5C,V[RPO[SJRXC< M@)T5L@;2# _OCD%>H8K88A02U1(NYV(5@ MP3 ^;>(PNW@#

[Z#Y<;05(2;^ &_&\VO-I=-)7T?>]KV8FG*T\$^7F=W/K%)I>F MM^NFG3<=*TI8+\$@>

<,NI<(P(T(7+JQBPF5?'R'Y?/R@#&8Y))CN\$>W\X '_AL M*I(^;<4*D'&-J6HV>D

M6%WJ%S+Y6GV5I=7KW)25Y0EI;2W\$JF)(&FV*D+DJ!NVJ_#G"B*JDZD*,)U* M;47R).2D]:**L^EM=\$M+=+D.I32G[2I'-

&DN:I7E*;4H:7;;M&^F_P *TMI\ M,VJZOIVC6=SJVIB#3K6*:>>X^S33&*T@>XG8106KS,R1PR-A8FG7,UR\ MLT&E:%

KP7BI#&OFK@\$LWF8W1_%_!9S_@K+IEU)>_L_!OQ;%%JD.H^=?^ MV:98_\$KPQK\$ECK?

AZA[AO[>:_BZ6UH+F\11;LV9,))Y@0FA/^O^":_O_!+; MXB_M1:M#\=/CK+XP@^\$EM;>+) \

A(^\$J)\$^(VGUWX?:U:3G39]#UR;7M=: MS2WMKI)9?+[+57C!BM+C+JM?MW"_ &39IED>(N-*[I49QBL->:SC2=2I)1J0I

MSI6]M*;C&44H.,M)+EVD?@/&7B+FV<9K JMP5AU6G2E)8[,Z*]JX14O9?[7 M@_JT;-JJZM2,Z?*X_.5&2/Z5/^"3/_!0/XV?

MJ]>%=.U+XF_#[P3X6M[JZ]?_ M_.D^%;K7)]I- AK5X+2Q79K.LZM+LGBD+3G;JXXQ&8N4K]P\OC;@]-V0N3P>V

+48\$'U(_ 7FOYE'_X*=_"X;?M&6_[7[+GA+X97_A/3])%]:]#KT/@3Q9X-UZ M>?Q#+91>*HI?L^D>%-_6W@NVP

M+M=LHD:64&0?TJV\$TLFG6=V1VGA@E/1 ME3SH(W?8 '+'+[BO]'W'70S61)#L MQ&@/.5W(RJ5R3R=GEJRD9P%

!.IQD#-.XZ'OCCZ=TG&4J3FE%M-4Y7E9;2J+FE MRN5W:R5[-[W2^TC.\IO]G5BXVDY3BU"2EH3?

+%/DY6FKMJZ6U@HHHK4T"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M

"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH

**** "BBB@ HHHH **** "BBB@ H HHMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@

HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)VC)SVZ*S'DXZ M*">_)QP.3@ FJLL3S28;*QH

R,A7=NROR(H<@E>5)"CAPY; AB7Y>:-@)) M5F# C&!M,8/(!SRI&W@9!\$8K2C)Q;;C>ZUTU2U???

3RW6K2O%)N'/AYH=XJ]\2Z@]C8VD%XTC?8KZ]B1K.PN=18^1865Q<.OV>SF9PBYS.S8,M

MC9-.-2M5I4J2YJU1M0IQ7/.;]RUDM=[7]W=Z.WPY5:]*E3=2I5C2H1;G4K3?

M+"/+WF^6;;QOZ;X=TZ^UK5)!::5IJE>7TMTEM-(HL+ M.>^N T%M!).PCAMIG\I\$W-Y>\$W/M6\ C_]X*T?

\%GJJNI:O% V?=7TC4;_ M2>=\$1AUF#3OB=X4UR2/6O%#W:ZS!-A(H#;H9C&DA\XI!8_?

M^"LO_!9"Z^*M:K'VO@)K>G2^&8I_'&LC7M.LOB7X0\02QW_(3N;3Q#:2M? M3:+

UG;7M[(B0&S5KCR8I')\I03#/)/@9IOAO4OB[H\GQ\$UC4Y_#5C=Z'K%SK MM[%]K6IRM9^(-

*O+BSGBEL;Z>>RAMENHTC^R!WC58D(;A?Z&\VO#>&H3SOB M'#5YRITO;4L/[-

PE*5U/ENZ'QF,A65;FP;INI3C!QU5E*,>:7-7.M(MGZO_![_@FOKG[37B7 (! M :!OO%E0\.+1_&E?\$L?B#P?XEG?6?

AOKEM,FESZ1K%&AL[A"ZI7V#^W)_P4#U?XP^*X?V.OV!=\$(77A*UF\\$>)5U_PKI_BCX0> M)Y\$U2T_LOQS!*^JS> -\$

O%j-^%> Z>[:DZI.6U%\$9TL_MC_ +8MW\DTKJC MS _GYI7AR^\.VVK>"/%U_QX@_-?KOP?5?V=KMC%I_C^*.XUIO

6BS65OJ&K ME/L8LFGU*1(IV7445Y5^IOA5'_VMF_.D\MRH9OF^7RQ&8RO@^&.%PG%TJ:

<9PQN9X=1C7DXQC2I*IRX>FG.HG%Z3/#_9_MSZWJFB1O86>H6-N&T9X8@%M]7MDO0Q61?,B+'S^ZR_,?YO_

.U=^V%?7?VU M/B)?%FL7DEGI/_%&Q1:!H>M>)+?P]"W@UA:0:C#I?B+5[M8KV>%@TSH%;>H\$ M C4;1_;G_P

\$5_%HU7]D71=*N)WN+JOB)\4+LBX%X['*4;!\$Q<3)])

MEZXCD/7/3"G<>.BY(XSU&0/Z 7\DW\A)%%!!1S G_)HHOOOY?EW ***.M\ Y- !1132X7.0 R<([<,"GC!
Y&Z09[C\N?IV';V_/K0M=?-KKT^7Y- H*^MOZ K^NCL44'/_^ M<&HBYVN&#HP#?-&K284[K(?+
(9\+DIL8]^%*N&C,A?5KMK_ % 7Y,?);,EH MJGE%)96.1N(QN8\B3&T"%BS'^R?N >VNCT=D)='8N,[8AD'(> M"
<,QX9/F?P)3>EU>UKVW=K+= -6%*4(VVYQC?:)]>NFFK5]MRS14&XN 5P1N MY^8C'WB'/W1.3QQP"#U\A
<].ZO:ZYEO&Z7K;Y_<="]40=Z2NFG[W]>G4HHH MH&%%%% % !1110 4444 %%% % !1110 4444
%!)_ +W';WYR/SIBL0=K;B1P&P MQW !1N8B-45B3]T<8Y' (4#7L/HHII!)W, !]T!<'D')RI;/!'# 8)XS@@ M=1110 44TL
0#NR1GA6(X(') (!Y')!&2!A6(0.#C ?YAD9CD'JWKE1M/S# MAL'AN/E;! 7Y?YK[UW#^OR S7WKN/HHJ)0=[Y)
++MQ@ANF<_+P<@J># \O.\ MD8C+I;M*^BOI=WV' 7XDM%00*BL%+,K9 QL;!^ZV=QC88V!N<@8\$O(,3M""\
MBE=P+,RE=H>-A SS)+*8E.1M9MI*IO5]TD1BW6[Y7R\UG;T?E;[KY;][C[E 0ERNP,9 T;G.W+%?*
W;=^0%51*IB.PA_+E-M)M-7Z/=>OK_6E MFSY/^DG^OK]ZO+13\$W MA+158*06D1G+-D#< H8KYF%?)QE5&?
D/.0%* ?/F/1F=BK90A00!GGEU)&^(M#C"D[7?!(!^7:TB33V:^^^ ;M?O\ @_(:[R>_3/_^KJ]U%(_F?8?Y_,CE M9I=7?
V^ ^ 6BBBF 4444 %%% % !1110 4444 %%% % !1110 444A8#&<\G X M)R'3@'GO] 3T!P +14;2HAPQ(.0/NN>O?A3QU);H
&)(VM@_J E?FR,\$XCD(MPQ !! "D\$<D\$@8;)&UL%Q)IW2;:6Z6MO7L1\$9G8Y*~*#NP!C&TYRT94@@;2= MQ(&0&R
\$JO(B@2Q[0C\$1X5,@,-H " 9PWWE PQ+ J%)(3,22@17+7*-)N<*K M(4.Q5V@;^800QVA2-
^3MP2JKF'S+XN_%CPC&/'&I>-/&=^NDZ7:VFH+:3G2 M]2U.,WUGI- JD<+6^D6=Q=HLD6G2,6*H
J8\$RLRI%,:560EAAL+&I*K6::C3 M4IRDVHR4DHKF:O)-63M9M/16QQ&*PV'I3Q.+E"EAZ\$6YUJDHTZ,5"UW*I.T(
MVV;:DD1ATN MTN;K);V\$C-A8QA<*ZL0J?PB?%6/^"J?B_JHCFX:JX*^\$&MQ1> (1X(UJ'4 MM\$;XA>%-0EN(O!XT_P
1VKV6JWNFQ_8DN[JZBJ33D>X,2S&6=#N2E P5+_X
M*K>, P!J3QGK/@/X9:K:6 PZMKKP;K]GK&@CX@>% =5N+RW' P!E^(-.N;35 M]3L8#8+J%W=H8FTV%
[KR8YO,EC#.GXFJZ^2I:26>Z#NSRS*~LQ3_D;5FDFNMVU%N;AWDF9H05,3M+%YX5'4HC?(NU?D"@;HY;)7GO-.D>X
MGLH;G4["UN9+)FCECM7NX89I\$Q'EI%B#2!0,&15 7*[(V^<\K;%B6*#!(6-6 M^7*E6)0)RPZYVG.!SNSY4-
N&B+1V8,Z1KYBRS;599!S\$-MC(*L,I@!UQRV! MA/W^K&=>C7PV"A"]*FU1G%VI]U%7ELDTK7NNZ:5FOYZ;\O/C7J?
B_QW MX+GMOB/X%UK4HK:0/\$MQ>W%E?PZ]HWAW1KH7UA)!9IIL?JN!/9CE[7,8,/X9 M^JOC%\:OVM?
&]WKWCG5=5E\$UKI?])C6WB76+O1(X/#^.;SN8[3Q!JN]JMPUO M(2[!RZ_ =A\E5*+Y!X6TWQ3XZO8M+EO-1N-&C N?
L3:HYLXY8)DCFN8].Z=H5 ME4%OG\M'SV(SM^[?"/A/3?">F0:1#"F89KFY%Y;6LE\NW\$I@:>"T7=\$K<(
MFU=HVEG)7"+@/PSC_:5?.L9*14K5ZBEBL572Q+M*~I[3V6\$G]\$8\G-SI**D^6 M"O+9-^+7CE4P.'P'#^7RP].-##*G'
4ZEFJJA"G6K8N"G'D&T/R@+Z\N""21T"](? ! \$ MSXKFR16?PSDEBBMK72_B'XA\$;1:B6WW=-_9R;LQ1_8>^<+&L_.'D'-?
@0\$DV M'[4GE&)]V1@X "L0F W #G(P_3 8%?>+&0#6'S/PUX@RVC15%)>.C.C&T(5'1JPY
M;2NX)12Y8N3G[E[W5H_CWT>>-*?N]J>+I56X) MMNTY4VT[R]U+1)K^TC:A=%48W /E4 (W8)
(Q&Z\GC*M[?;36K_GUK'@(!: MAEI3# <%05);:_7\$;SDCIF0YZ<]#L#.!GKW_P Y\S]37^4) _NH[7BW!M=
M>6VK]=7WTZ67^Z\$-8*2=U*+72STL[/2W2P4R3[C=>G*[C^"[' MS_WPWTI](Q&"6Z_9.1GBM%NO4=
[:O1+6_P#5OS\$R)(W'!)&">4;H.IY7IW!Z\$ \$ M\$9!%4FDA19)3M0)*)*! #&D:R,SIFTRQP22#GALJ#N^>6TI13:4I.T4W9R]
MZN-5?:=^B]?)Y=;7F MFZZEC#J;64/@KQA?+97,MS##<+W)D>WG#QF4R+M&4*RQF;G1_P40_M9+C92?
B)>#C=M_X07QS\H?<-RA?'F_+;CN4')PVW=D>;WPR3/JE14LGS2I"3 M3C*& Q,XR3U]UJD[IKM;RV]
[Q7Q)P]%~LL]RB,DVFI9CA(M;=Z][KII>UHIV MI?=%%?\$(P""BO))./^%CZCGCKX#?<9V]_ ^\$;Q_%QCKCY<[X]#?
!17] MDU6VM2=14LN["^!?'C;4PQ#KM)*~N8!94Y^Z-H;S(?M'4N'L^;45DV:.309 M+ 8EMV:3T]ET';5^U]1/B7AU*
[S]XKO+,<(D[^;JV_X?L?Q[@=P&/EW903P)_P45_9-E-,GQ*U_#<4 M)_X0;QW^[()7(W>\$B2%3A[B.+LLCS?
2S]J+&V^O/_KI^([I)TN).!5J_M\^R=+? \Y&6#V33U_>_KIW3O*~V\^0"-N#ERI5&P"QE)=<6^-S8^;.>6ZL64 MRA9QN
+C@GY5/RC]Z=R 6K;G)"Y7YOX3@E@)OAMO^<#BO[(R3^2?B)?V3SLC MP%X[*B,^9ND+?(D1P9@6_'=?TGQ98?
VOH=S]KL2P0S&"2W M822VJ7D8\$-S9I(/%O[:0#RV&]6&]OWHN>7%9=F. A3EC,!C,*YI+~+8;K:0Y MFFDTN>\$;Z)K1-
WTO-VMK@D?.B<2&.,C!\ M +N)+J^'VA99@&/>KHZ==_G[7_/P4,^!O['5V]G\6_\$\6@WHV/^&?\$7D_(AXT\21
M'20%GBO6O"6F7>_PQI&I*YFU/1]1MUMTWSP8:XF5H)X#J/9E6!QF9UHX+ T9
MUL55<(4J<*;G*G&,>.;,RY5+>7PZ:MV3/*S3-<%E&'EC\RQ.'PV%HIU)U,1 M6ITJ+<*;G\4_A)_P6
M_90^+7Q!TOX>:+XZLKW7=7TSQ%K-E8K_-BK9B;3_#WAZ^UR^N'O-2V_84 M(@MKB581:4*]&8U> M?
3<7"+A=QLN5O>RT/8YG/WG]K7^K?:=IV"BBBK **** "BBB@"IA"N 3E2%V@.5EK1*\$#J\$;J\$!MQ[G'4?NR1G@D<_,?O2
Y< MU"0Q,DB1I(V8T(=3M(D=HQN8(>FY@,M\NXD#+;);Q:~W_!;3]D_X)^+Y?!O
MBCQS96.LPI]+SVLOPW^*FH!3IVK:AI-R?M.E:#;],J7-E/&=C,K[FDCDFCFA M:Y]#+586O5J4-.CI49U7;1J7NQ?*FT[=
[;ZV7BYSG>49!"%;,; MA<+3KV5-XG\$TL.M6H[U914K]*VEF]&[M_M4RQ.06=QC)PD8(RVXY!\@/@D@#
M/.1P=Y\R\.@^@ZC'Z8&/I@8]!7Q5^R?^V=!*?VMO#^I>(OAEK\$&NZ?I>N0^' M[V8>/'%A>3J,_A[3O\$21B'Q'IMK-
(#8ZM;RF:-7M_WWDF5IU?S/M/>J@)Y'M'3:V.../E&?P<+<P56G7P]5?NYT:BK0:6FDHWB_DW=6Z6'T4TNHZDC/JK?X?
YR/4 M5&L3]BK\$A#M;Y'X\XKT/4\$<\$8(".*QL]"_KMIOZ=]SJ?NIREHENWHEZMZ\$U M%1B5#C!)SG'ROSCCKCY>UTTU?
MZZK[Q.44KN22NHW;27.*W*O5W5EN[JQ)135=6SM.<!'X(_F!D>XR M*=3&%% % !1110 4444
%59@VUF."H(V@G(*D2?Z@LKKS@;L>K9^9/7_ZW MN.^"/U_Q%6X);,80-MPWS?+R".A:/,9!W+TQD=LI5)QFHJ-
VW[BLVVTHO3 M5)VN[^EM]VN_ ;5^7X\A)E:([*G[RL3M'##?)\QS:;A@X)P>/X=O[BP]\$, MV0Q^8'+*~'&8>5\^?
LP^=2,@CY?1L+B'@O%OC_P_?#S0-6\4^++UM/T'0K63 M4-3NX]/O+XP6UJ4\$LB6UA8W-U*?
R@)!\$SLV0%4+^X^8'_X**_LC1W%S ?B/ M?>;;3>5.H\!^_OED!7.YO^\$6P2IC(O)W&TDL!&[0^E@KS;'P=3!Y;C<734N
M1U,-A*]."FE%N/-3C)J!-/5)K38\K'9WE675(4L=FF!P5><5.-'%XNA0J3@_M]G&G5FG*~I!O?3H]?N9<[5R2?
E&21@GCJ0%7!/<;5Y_A'2DWG/W>,CDAQP= MO;R^_I][N3];\12?%\%\$?V3%2%1\1[_JH\L_P#""^/E#*.AB,>&% QM(P?*
M;(Y6\O;(4@;_ (*?LF1/&^)%^~X9H_~%~>8<(P4X/_",D @X*@@ CGY0C M?9N]<-<0\GM'D6<*S!W6V[_2]
[:ZZIO=7^YZ8S\$ \$ +DGG/SX_W*~R\;KD!L@C\$=CLH9E^_M'4_X**?LG.OJ_\$K4'(P,?(/XZ&X<99C_P (HH5CL?"Y5?
F^;9ME^S2_V#_M_-DI2F^^(^U^QY*~LW@3QVV5C&2YQX70+B1,].&Y^5HYD@G_5OB!~[R3-DKK_F
M'7XKO_P!>M&];>GI< P!9>K'U_MW*+7_Z&.\$KK^&-O9_+=Z-7^U?F;9N!;A2- MZ'D PMN;J-CJV2J?
+D@G"D'R6+P5RAY,97=& 7(/,SMMMLK(NT%5PF_N3MV M'[/AI^'OVX/V9?%5VECH7C>ZO;J6XMK=(CX+\8VNZXN?-
NI>[T&!%)%H];G_M95C6+<[[(G;T5X>\6>'_%EJ=1T&Y^V6GE6MRKO:7%HS07F'MY/*O+*&='Q: M2?NV
:/RE\$OED+Y7%B,,-BZ->8MP^X<'=E648_M99%1X>'W7'F:YDDI*UY:JR=K7;W:=K[]>OHV>B=UKJF[-JTN9;K?
KHOM+X@L_MC;F2-6?J,QMN+9C"DAHQA@T8SEA@PKN9=C&*NPNE=?+M8=@/."@):*5!V? M,L<2[+?B)XDF6S\~^"?
#.M>)]>OC8WMX;7_M3!M(KV\NC::;:O=3^1:PR,;-IF,*QQH@B=[7\9_%?_!>O]COPWXHU+PVW MQ&L_M&D:O>:5?
B7X8?%M%-:O\$[/9%X>6'Y51_WJ/Y2>2&D6\$),+/U.MR#.<
M]A5G@,!CL13H*4ZBH8>K54%",9/GE"G)*6L5%/ENY)15VK_/9OQ3D62U*-,
M,=@<)4K2@H+\$XJC0=24G[JC[62O%V1&_HW8VE\$B(4;G_MB^9/V7OVF/A_ ^U#X(TWQIX
U&'5])U3POX2\4V]RNB:]HGF6'BR361ILRV7B M&RM^.(?#MUMAEB2>U:V\N[6-DC2#Z7!<2LH3:%=0-
J8^1O+&>\$!.A54\$%=@= MK(H5J=6E4A>E5IN,X35VN:\$US1:3NM+ZIO6VLT08 E@_S[78@#DE%7GY(V+ M%*)9
2,8"#J]U+4\$03=*ZLY+E2RMD \$+C(153D]S'<04G*B%8XYZP3;2; M5KI.UK=-'TW6OS.FY5:=-KZO??K_P
%M]VWJRBBBBF***1F"@L>_2<=\$X'K MQD= 0<@>;0+WKIOO6=G;6S[.W7RW):*C M:5%V[CC?]W*L,]"<
<8!RS5^UTU:~J]UW\$VDXQ;2CD^T4]6]'HB6BH_-CZ9.>!]Q^XS_ = M^N?

[illegible]

+U@>*"MM:\.UJ,/C+7 !WJ=BGV^%FNY+>(Z?9^);&6:VO4 MU*Y% _F, _:#:0&\$6C1C[/; _/ &/ _@E!^S?
 \4O#&N:*.OM%N+S2-7T^WFT# M0 AWIUSYNIBVS*LT @R1(IX/LB 9Y1L2/<^?+%"%+7^&; @H7^RI>_LC?M Z[
MX.,%()X1\2?*\$3XC:9X)N]2U'0;^YOM"\&W7A> SS0>'>RAL+A5\1V;W*2V-
MC\$^Y5MX8!!EKJ/PJQ=P=Q]B:F5ULNI4J];#5HN:>O-!2E&UXO22C#[5N9Z) MW2?QG\$
G& AEAH9S@UBG, \L124E_.5"3@JCE:I-Q2J2DES7LFK:M\W]R M' !;_ @HUX7 _&T A^#(/'- M2\$1>
(_#&DZVCPSPQ0@7<(E.R.YW7%:*HB91&KRIQC37*U=M;112:O&+3<[\ROL[P!]>#WB1+C/)(0Q\$5);RY3IUY6E
M>:Y>137, LNI[-OJXW5KM+Y<_P""D<%U-^P[^U;- "C(T7[.OQ<+ .C>7(3 _PB MK.92_EH5*+ "S;@8RBQH2\+@M:?
YF7Q*T^9?B+X]G^U73W\ PDNIS)&S@YFC MFN"N&,2F(;JO[QI(Q\H.^+[,9+7 _%#_ -
L;X;ZK9/V8OV@/ACX>#V>Y+DV%S99I711E4M!* =2\$?:U=6M-ZW;LM%RWN]_US? M>.7#>?9]FF4SR;#UIJ')-
J%*=1RY/:2GK#2\$>2%V]>9KE;LXW _I. P""\$, -Q M!^RAX*\U2 ?@7^SX\$#2;LE#4-
YV8RNP;1_J=N4V^9%Y31V7[D8C+,\99I&9 M2%8'&X%,X!0;B-IX8CYHRA>,6RFW+_C _)(5_LS>-/V9/V? _OX1\;6=S9W
MD/PM^\$&@NEYK.C:TRR^\$CXXDOP9M',EO&\+ZY; R>4(Y %2W>!K>5+ #]2D.; ML6!8G>&XC(YQ"GS?
NE/#)M/(LG%N M4'RPH)MRV: +CR\7B: \E>#;::I2 MC9- ^[=+WDTR2(, -P,.(,C&P# #8&W)QCE555'&-BJY! M13R&1""2,
<\ 9(,*(^OFELOPZZ?9UW>EM6VWNW<^M>[]?7UOK^/WA1113 * M9(-R,9R. \]?C/ITY_B7[P?
2,1@YX'_0 B>PYXQFAWZ*[Z])7T7S8T M[-/S72_7L42BA7+9&%#9V87Y<-AMR #8
!T4#;3N5D^=X>KWEAIVFWFJW5Q+ M%:I!O<:A.4A9E6&VB\$LCO&D#/,L<<.65=K?(RKY;1 0[A\$8PP8L!MW;@JY4+
M_0E(JY(P1C *@878/+X;X@NT0@3QKY<;# _ (1?7,'RP'8 +@9&1@<QKV MCQM7>T1R;:%3]K/#T<6E&C5Q-
&#]G=73:TZ]=5&UTWI]HPK36&PM6<%::5;J MG)W;:C)I[K51N[ZJVK;LK_A3^V- P72^&[-
OQ!\8 _#K2[_PKJ&N^%-9U _0Y MK;6? OQ.NO+N],LK"XM(C>:6EG.;TLMTR3/!(L:HB[7@=7>W[+_@F? \ %4O
M\$[/= /C;XG:3/H @BTT PMIOPOWH) _#VC>---F>/QEK'B[393(/\$>I7RG: ?#@ M:W6*!'BF6
T>+7]FO^#%;%8&^(/[1L;1(@C\ _L^>4(X8U)QXN^+!.Y?* &UE M'S;2ZXR!\$<"W_HW.^
>\NX\$6<86[Q%3#864YR:]D,CK2_V/#XW'PA'WTDZ=/\$?\$F[WC*+BKVUTL[V?]G.(HA M%'))(XP,.K-@KDX!,
(7*E<\$8"@KG;,+F+5MMWDINQG"."2 >XR<\$ \[_* _P"Z M*H3C:'1U41LA_?!O(^+EF6-MC(J@A@@'
((QF&]:A!;Q",LR!0%+ +M..WR[M(\?380TK^

1SD8! ;QG\X@O(OB&J+AAx)7Y95 MP7 \.:D5C+>5)NSD@XR<'E7W!9:R[E>8X>,DFI8B"\KMK5]UOLK6M6OK;SLP MERT,3)1H7\$;7*Z-
9KQ#.;JUR8WD#RD\$E78*JR,) _Z/_#<=>U,/PSTB07%Q;/V\$PH(X=)\. MRLZKEF\$NDVBX;JVXQM=6Y1]V0#NWD\$?V)\ _!N@RS?#O3H
'E'PY?;I*A68 MI3_YD,2KJ5Y7((E!);[ZDO-_67B51HX; _ (@>NZ,=92H,[GE]*,89SM SCYL88X:3@_NH^!GY?F?Q/&=SRU_)
M;_R+_Y_F_5[O^Y%LO1?EZ+^NKW;1]YN.R]OKWVC/_?38]![NIH^W'9>WU[[M1G_OIL>B]W4/?Y+\D4]_DOR04444A!1110 4444
%%%%!1110 54V<&00& M@B505?Y@023G<&QE0,\$M]@ P6VY<0VCT/;CJ1G^X<9_5F[EC9G<[!M [YO.-
ERI/1WYKM=EH^JGAGEDD8[5,'1'42;MPVAE8\$=0Q8'@ 8&>=X2*6Y/F M-((JBE&)._ (7_YLIM*L<@#!V[-S;6R8:"^?;R30,%6
1'\$P.4F50TCC:% M"L,MM"A5"]J@&[L7P+^VW^-W+\OV-AMJ]UKVM""7I'U+0].@U/PWXIU:WDU
MK4!Z6M>?)\$MWFV/VMNRI5:/6JR7/VJWAM[<2PO+;RQM-;9;@5;G.>("P%"5 M>O*3A*\$8.7):5I:2Y4GIS-M)\MK:VX,TS; 91@)YAF^(I9?
0248<XT^::A M[1]/X >DXPE>*;<KFE:RYEWW[7W[8?PU_9.^!^K>(& &KQZ9=A=3TO38I?#_ M (CU:VDUIO".L>(M+AD70;02)!;"+
[1<">*"+\$I?%NCV(U/PKX1M"/U]\$-(U[6M0,<-V;: M]-Z[63W,QE>.<02%(O/_P!K][L[XG_MG_\$K6/'?BZ_BT?3-1?PG/!H_A:Z\
M4V6@Q70A/PKIWA%>+TS7]6U9XQ=PZ=]*^C(US=2SRQ&*W98;7Y4*Q6Y:XFB M\$ F
@6WCC!A0J,*5180!O!O19F*>8&A)%M_6_A_X88+AO#X?-,WDJN.JTJ4
MJ49VC(G)QIU&G#NFDKI1]YIKW7%:1]W^&O%OQ>QO%&+K91E5=X? 8:K6AR4W[
MF(IPE*DIM6:E)QD[6<8VEJE)PE&!HXY\$SQ010,3%Y8"YE#,IS'Y0;8\@92S MB,#!>1\$\$169(C;KY5U\$D'[PB-
XHP=TA50+5F6*3"N>X"KL8H(U\B*2UDN! MLB3\$BGS'3 153_9)4;Y!) W#!+E-N+>*XN;'30B:G+*@" 6S;6E)FD5I(4; M%N2L9
QDA!&!M/EA5,'ZU]6J8RK4Q#DHK#RGS3E[L8QNKKW6DFN6]EJN5IV=SI7B*"[NULA]EU!)0=/C%SL7[-L;[5X3_M _OY_P#!.?XG?
MK^.'J'UZ?1KN^X=Q10JD&]:XF*Z3?2W/A'QAINC:O;2V' MB!+R7[L]J0WB.GV*,W1C4VLHC8(O^@A^S3^S/X*_9C^&^E_#[P-9O]BTZUV^
M2U"\#08M1W^=(3?5K^<-I]T[C2[4P1W\$KB +;))Y:KY[R/ET_0%\$WQ)H91A5E MV4583QU;VT<37A.]E)TXQ44XQ?
VW)ZRB[F^UN2S_I3P>(\L1G>*IYQGN&J0 MP5%T9T]-2\$H0J^TE&E.HES.*5ERRT3?22<=WX#?L]?#S]G_&: ?X'\\$;7' M#96-SJFH+?
3Z;H5OJOFZW>?VA>VYN-%T?38/LHN6(58HDW!09I)95RON;VS, M?,Y#G (WAE4 !>/W.Y@<9)8;N@PH V5[9=L09<,RNY+/R0,C>3^Z7
X^Z"J# M &% ^26%4;:[0K,25V\$9!1<8!VCRU.3CJ<' V]!M7^4IUJF(E5QN)E^I6K2E M.JY:RFI2C-Z.Z2N/W8ME8N-#U*49KB!XU7=(#
MC\$9! (^[E/X% C^X9_X0WQ_J7ABZ1HO(M;2_4L89YU-[YLZ))+_0_9IA V% M%8_OAE&W_0LU6V6?2=3ML,1<6%];\KDJ9K>2-MA""\$SOZ?
*!Z+@X_BC_P"" MHOPW_P"\$:3UWR[:6"S7PI.E#X%[4_O+S1GE),=K:Q':7'#B;ZONVY3^M?
MHEY+ #Y]Q\$PXYOGS*CK3P3LFU3KRY4M>9XZU% MJ#=? TRO^XG+O:P303CF5">4KI6T677UCTCL]OSJ7\$D@;:2"H0X""C:0=H\M
MFYQD#8@/=0 ""Z?+8H 0,94X.3 MDC!S_P!,6!/H&W\$GDH3]T-L'G+X*YA 8[01D*>H,8!/H,DCL!C*_WK\$QHS
MXBUJN(J0P\9NUZROKI_5=_P1=^%YK'P=TCP+_3'_P"1?_@C#35T+XRVWA&[E5+ M>#PIXZU\$*(V5EFN[BQ*-NB62W(9B
WREUZ&85_6_)JLBO\ "GK966ID MM;?[H_17XF7\$WA!PXWB?K%?*L+ATTM9J[30M/&[M."2N/F8=^@Z=1GG_
&@AJL8)85DD8!T14'.5V1QP3\QQM#@97RP M-@YY5<8YW@V)DGJU[6U? \ P-[NW]&IN+6NO_ 6VGSZ60UUY00(,8SPQ;^\$Y)^JG],9[YR-
M+/RM8 MA2!\$^[GJ2_\$.TD\$G?/L2"T6R Y3UP"L6!N+&D 1@_G<1GKC >;= M8HJG[V^O]?U^/=CBE&W*K6T7]?=?
GY=D1>4H(/<9P=L>02",@L@X8_UR"<_G M]_P4L3=^S!K:8/_\$J'L^<2<7K?=@U8!2.""%P3NY\$A81S?H-7Y]?! 2H9_M_9CUOY2?
^*H\]'Y'_\$_]@&3_*.V1SRO.I.W:^[RYO9X;26?Y(K:/-'=? M<6*UNUT\TO-;GA\4)/A.F]7_9V+5_)X>IVZZ+6U]\$?YCE^I'INX#'/BG5V(
M/,.:BV<-Y329.X# RQR .&47/]NG !NI JPL^7;'.3=?BZ2-N4Y^&_PH7=C
M].5!QCN&.\AI2&4771FHC/[N?G)'BC6#TX'_\$Q;D#RVR1NPHV');H=^E?V M\ _!NL,?L]7?RXQ=?BZVU4W _\6X^%?S9\ACN^?
HN3\YYQ(3= _U5XMI2X/ MDGK=8>6^K?L*_GL]VY>5M7M)^OXJ]'YO\ U^?-)OM<8M=K1QF!N[;+;FE M;WGN_1?TP')'(0_O"N54#(P3G
0G+;Y_5B,JW'F;@)]I5RLP&G<<8)UE>[3;:_@G=Z23>D6 MXXK>=>-W&G/858#AJ5-2Q6"IU9"XVKS1G6Y")J]&H*,O-2C+W8IQC? _\$O_
M (>G&+P3\T164@ MD97@D2Z6%!.*)8KG>?9?P+X(D4>*[KR]3:VESQI-[J#?9K^JET^T8&UL[H MD2W7G1>4C,RF1]^3<(U_#_!\$I?
A=XV^%?[./B/P]X^M7M]7N_BG-J]\$4NJV M6L'[!+)/A%HV[[19S7<*[! _ \$O446\$^6[H3.WVI+E)-0_"G_@XV;:^-O#WQ M\$AT?
PWX@U00].E^!'P6U*632=9U/3)OMK?'CXO1LRBTF@C?[5]!!, [1W#3Q MLL?+5GA7S4[5]J4VW"4>?1KWO>C;+)-.V?U,Z+\ M?
_@SKFJ0:=8:H)-1FCOY(0/#&JPN8+:&6ZG87#:7LVR(TAC\$A\$V[8?.,RM> M^XPQ[XPRIN28+K[210N-Z3RNT@N)99I&?1-
"=WES/O,Vd6<.0D),\CR2,S'YVD,DT8CE M\$Y6[ZO\$7@F/!&P-&*J8IU**E[[@^7]ZH]K2N^9S;>MHOF,N/I.KK%\$JN[!L 4=010+2,"
MJE2H 8%EWX+Q-NE:2\$7,AO#Y>Y K'A>C8+&\$K\$SQ:N#GJP.25=P(_/2/VP/V MD;+JE3X->/(B12%8 M)AY<[^9, HF,5_\
P=?'3_@KC^TY\6_\$&L7VF)X;TG0+2YETA!_#UY0=*82 MV?
B;5M8M)7@N_&DK, \L6J6D4@B9&MGCB(9WO<.\$/W/>+H3KX2,;=#GC2O M9RY&FN:UGKRP<9-^ \];/?
COQ.R+@).EBL_7<7).2HN<5+F;M&.B3JZ7,DK M/1-H&N/E#QK_ _%5_P!CKP7.;34?B)J45X;>.ZAB/P]^ (5RLD37\UBQ\$
MEIX>9"QDMY%10_*R*9C(@^T?YU5_P#&3XW?74<1^_O%5Q_9E_ :F?7T6J;:/W^L"(R6>
M+SQ_IL4;2"W&H2;A?;N;@);@%=Z9F.W[0T[?;OU;#>"V286E3J9KQ)"E/
MVLH5:3JX6+@H*FY[Y4MU^~5_ 'WB3%Q?J]D.1?/!SA.IAL9533; MY?9JG*E9.TDI---J>TK_P!Y0_X+2?L?=-BU7Q_.2X+) _P
6U^)WS(HW!L_V M'@>8NW:H#%\$QM\PF!+KZ(^ _/P4H_95^ (=U;Z=HOCN_N-2NA_J]?![?7^GP_VQ?>'6ABA>%,Q? M\$/PV^U+N9(8I'5-
9GD)FDN!G.<;_ -X)%?==?.&M0?\$CX=WPT_70%'BG1=7: M&:XM_P"S?)[(PM6>;3IYOM&GSRQHS36]U"X,A,T<>
[RY([G_3=H>#W""92< M,KXC55QNFUX<+)QDHO27+_V[OJ]MI;G\$ _WB[+94%G608:A"=2FYR^JXZFU2 M=2*DHRJ8B4>;;V=IQ3^~M-

G^L9I>N0ZS;1WU@R36 V,,= @DTI[F2\$ARB^2 -[XD8@DD 8"C&<+CAB68+@ \$IO_AA_MX) _\%/7\$7PW^(&B_!+XS:W9R:5XJ\1^*/%2ZI?
VWC[Q/K4>BZ+|= /L-.% O M=V^J^A:K90P2:CX7E>XM);*69) KND(!=0+> %LPX.S..%Q'/B<+62]G7J
M0:ORM0M+Q*16IY;O=M*Z=U\$^J^S^1.-<^QOE+Q> \$E3IU)=*4Z8<!.17/&I MO%*47I7C).ST-Z211DVPQR%T#1@ @8=< #'!L,5
\$#. /FV[B!UC-UXEXA^ /W MP9\7GV'7]4"7J(Y.-?#>J7!:15GFAE*RP:5,A"SI(K 2%3RP+B1#+|/<(WD\$ MJ.3<69WJVU@ #
<)D;@B[5P6.T2#>9&#%UD)G _SC_@H5\4/BM-^T-XHMM\ M%_BBRMK;40&EE"9>*= [RV11MWL 45=^YEN:/> >
M]! _/ @WQY87M\X70#/:6UXMO,1IU MQ8,+B2UCO\$417-E%,^; >YB9G".A+%-I@L).YF0.%50=C#EMAZYXQ^Y(&[, MYQD9/F?S* \
!N[XV\8>+?A)\3)/\$VJ7^JR6WQQM\I)9+ _4; _% _%(3X/>)F MVM?3W;8\Z5W(B(B+R-#*OF9Y_P"G"5<36W4CY01W.2/).#S_\$PQG[W],GS?
M\$F21R+B3\$Y6Y^W5"I)"HW=M2HP5FXV3MZ?@SZ7A+/5Q)PSA,Y+=+V;Q5%U%&+ M=DHN7*U>3ORM:07WKH "W_@NW!_QB3\4%.
[9_P(7X6#L,C/B:8&);<02 M,M(V"05P=1W)OP9O+2R^-_ANZNI^CMHFU\331Q^:06T045C(2.!F8L\16* MH3DD@.IQ)_=[_P
%V8_8]^*LCS=[37MZR<7>[3G%MU9O33F3;_P!-/G _/F^!^G _!;X96ESXIOS M/8^ O"=O)[T M;NR>&/\$*\$G)(
<=>'.&SR0,DYX4\LO_F26]W^T)"96T60>(8--N8]E]E;Z MA\$19E2+=U1-7"1J\$ _'D%%(Z%,'YT:Z^/^=Q%Y'BSQ>=NX,9/'_IA ^"!D?VF
M!@9Z!CSQ2#)\[+P8R;&5'7H\25:=6>,FJM]= 'FDDX-MIO7^];W:5FUS?58 M;Q^S3#X7"8.CPS[6IA)\3:FIUFOW;U:IM+2-
UMTO=71_ILR?M=-N_)I6\4 MW:QP-L=F+^ (B1(XU^)]CN2< /,F!^G[3N]K_M@? 6&\$7\$WBN]2\$]!'_X1/Q M%N;Y;1HS\$-GG!R=O)4 @G_
#,%?M/[1K_NHO\$?B9BY^#.A.MOY8<*>=7&=W) M(O+?>|XSNXNZI(J@BO[4XY=RH2H9^P4^20DIZ@) (G<Z; _MCU;1XJX?
Q7#.:U,KKQC5]3]_P"!N,,+QKDU M#.J"ITN> /LJN^IUXU53J\W.GI= \IU*^:DF]]-+7=A)DD^X2W_ _' \$E<#G^O MI3/-=0_F+MQJW 8YJ]2>,>=?
61@Y!SQ 3N^&!N>+>R_? M#I5#);&|VC!*XQR2.NZ^<,9ZDJ1_LMS7S4YIIQ@W%M6--!87U\WV>) MQ'+++LLK:Y8E'9 4 \S&3M(!^*56?
[6OP5O9X(8/\$MTYN)"(@?#7B2,O@%@3Y MFE+M9E!VAPI)!#! /Y8O^#BO]H[Q#8>.>A# \ P7X@O]/LO\$P^P^*6FZX;
M"Z0:1=PWNF^,?#T4+V\MM;:\VCK\$T@\$T=V@4%4>)"G3E42?O*.T8JHI15G&S5[_>)/ M&AY7Q3+AGIY?2Q-
:KB<^2I3A[23ASK^NHDH*6#S(G,D,Y5253P40@E-O,VYIY87H\$J]0:XGO _[X0T+1[R2]=;N=
MKK3I.&"5Y+R!'BGDWIEIHMJ.1O&SGR_5T?P!L!)& /X&] V?*&XZ?*,X7! MV?
C%>FL.ZT*-1U%3Q4Z:JM]7/'VG*MKJRC[09V6KNV_WBC)XC#X>O4I\KJ4* M4W3Y;./-&K;7YF];:]++H?C9_P6T\ QAG< >O?
@QXU#94G<%NM*][L,< M\$9^KE+WMJTW)6M;IK?_0A M_P""":1!^S/[I;N_P _.@J9%*G_K_V\XM&U5\$?&T Y)ODX_UB+A8OV],>QN M
K#*N6P/E_V\+@/'ECD@#*#;:>\$,'XI? \\$.W8_LTVS;%V?]*]^"LB KM&XZ M1XL^SZ[IM]]])5&6-9844G!8%L@
MGY5,8X^V=55&RMA<Y84P\$2M;?Q;? \R-X;TZ#QM^S]J?6D"#49Y?VH[Y=]?^B_V;:Sf=GH=G/JU_MAT_3('N[^8) M)-Y-O"L\$KJV MU-
AX3Z :!>PDDFZUICOR: _= "6D*%6G0KJ\$).G4FJ4E3Y!E!Q2YN5I-2GW=I)W>C_ \$O'3&9=0X
M)Q>\$J5L+6Q6,=*5*C5G^W9T\30DN2DI*I%3IT9-|SES_!1WL?DW^SC))?:M M+?LTS8/VC_A9WAF::EPLP\$K?|
(U|=AM8:Q':S6EL(VUG6FD,?I IL+^8!=\$E=?)P8RC"78VW\)_MI8?"+PW_,(3!+OAYX4N(BG_C?A32=)9'6&0H+"V@4YDMHDAS\$8U;JQ'!\$
M"F5@A"E;:Z[QXK8.EBL.^*565;'P]X>O.JN:%">'IQY\$H^T>2L/-HY+FC^ M59(RPPNJQ*%8J"1I)&*VGAMU^T7| M#(M0-
A<:MNNDN\;21GPOK.#.)0FPR'7Q'LD>2LBN3&8_4/Y'DR^P\N_XH*)7M M_I/[O4.M:-: \$QF'S _W?XE?%CXO3?
\$GX@%&GBR&8>)=1DM(K?Q7KL^)+Y@4@ _@AB6, MVJ_-Y"QH&96MVBB.G?(! ">CXQI9A66*JT%0AS5!)1=2\$*+NT[VZ=-TK\V
MD7^A>)'B?#@3\$Y92GA*5=XBE*5ZCDVX3K5Z7*DGJK*S3.QM_/FB4,7MEB>6+ M[-!#8_N*?+E4+",O\$FU 45-[?NL;AY "G\$' 4Q*-A3;1/\
9OB<JRUY7FN- MRI7J4|-4C&=:2=ZC<83?#,>^(!TW867&!\2H1/E B4<\$L-Q09,95A M\$=\$;>?D?&OQ(\,?#K2;S7?&-Y)INE6=EJ6I/<06-?
L++2((YJ0D:'SMYI1)" MDL>R+8))@=T:D+ +?XU_!U_;<|#_ +&GPBUSQ/XAU"UM_% =YX""^*.M^"-O/ M#_B;5J,U76OAYI/AZYEL[V;P!#;_
&2V2?Q)3!3LU_I\LY=A;3VIL\IM_@P M_'; _."DGQT_:Pl=>(-2;4K/P_X,EU_QM>:\$_ @K4/'6@1WVB>,X=#ADCN=/U M?Q-
?""RB1-0R?:26ELMN9\QIH#&(O/-^MX)_XXPJ]J2]_IUN/J.GB9VJ M^~2A-|I|0>56IRI]73DE%|THN_P'GBMEG\G-
A(4*> /S;FB18-3;V;C*JU7 M6D>=N3H5(U&^3JZ?)5L/[M/B.P56_8^ ^KB#50BJ], QDU.##?#WXA^B M;38[9I@WV;P\0HB-
W"SEG4.@:|92Y-IXY!_P6I_8XN;Q8(?B'.8)+A(XG;X M:?\$U9&C9G4Y1M\$7#J5QN8(L,I\ '76M:|<<G& MW5D-
1J|@LXQ+J.AP1J>&SD#N\|8O+4!A_9/M-2?\$_MOKJAJ>F%;C3;Z'_YL)H(+BW>6-VD(-2*X1)(2-BD++'\$P^L6V_'2'_*S\8>-M
_CS!^KZ"Y67^M>^3%=WDL+Z9XQ-V\3>^1:RW3,VCW\N#9H#N8R/*SYS"\$ Mj(&%G^AW\!7_5E^~7!-GC7PUI7B&|T;Q#1.-?
UKX<:3?>KXLD^<(B35K^P^MYX9U/6Y-2OM/M+Q1\$5^UMK0:Z273F2[6RL46UC6U?R/(S_,'*++WF&09-ML(Q7)S2PZC3K^ZK1J)/#V?
NR3BY6D>232TD_>1CS?+*?>B&2?A_XVC90B1+WN^3C_CPF.=Q240JL@*RXI9 M3_JF7,X/9I%#87&?
5L5AY8:="OAVH3C*\$HR=2DW[L\RVES)ZJS;6C3?]%0Q.M\$Q>71Q^Q4<30QF&K2H_,X3A!.E4=HRA>[5N5IMV;<6^:_!_@IRUN/VUO
MV@H69W=;B;K2(^,GV3\ECY("J@557-J{#D@QE66W_ _D_X-Y?B5X(^&C_M;X_W?C759-
*AU;PC\!8M;,&EWNH?;)K#Q3IY+K<+&QNOI20Q3P2\$RX#9;R= MHB/V;H/^"FL_STH<35
M>%_\$\$XZC@OKN(I9EF\CFY5!R=:\$G.\$)23:~?~RL^XK.TO\B?JKOX"/+B M3Q9?
DK(H0#PMXE;>VWH5_L#1#>07(P2#ROEL(+5K^UK\^IVJT_3K+Q=27.H
MW4=G!%_PBWB%\$>>1D2\$;S.*%*EI\$V8^,&UO* _5+6D_..E9Y%|0^>)0!.6D-M0>.[Y1D% ^6U9_!0V_Y7@Q!1Y'3_#.^ ^AGQ=^\$J-
XC\3O+_PL/PTE_?&MVIF 10JEKQAM54%2(W\Q)?F4E/X A\$^Y+7%|FP\$747\$5*K1CAY2@J=7#RYJS MY9>]:40\VB3NHN\TKO\>
<)X^YK7Q=*C+A?V2JXF_&EW6E;HJG^ZO&ZTO+ M2;
<8J+YN5_ZE&FZK^K&G1:MIOEW%67!;C3%IC(1_STS_#QC9^ [X7]NKJ\KPK#^QO\KQQ7X
MBU;0:OXGT;QM%X5M=0T'Q'K5E=ZWX8T2VU(6HH^LDUI#F_MEEEFN;C)1YOAFHOX>G+JN^&S;?_!0U3;|A\H6=Y
MCU7J8&DL)1Q?I222HRR?\$(4(YD>X65)?A_!09P#M;^<K8?J?5LXWDG&O#K%?X-?VO+ @H+! M8OVH?B/XA!67?
B"YT#PGK6KW.H>^H"/>J>_M^LIGOM.M+!@&EZKKU_):6Z" MW5E22& F4L79TXB\(|!_KX_%;>^!7&M:Y9:GY^V>74/&MK;ZW4IM(RJ
MZX?0M&6=#^LE3;A07VJH?NF6>#&"65T_QSW/%@JE5)RPW\FARMSY5&J=REM
M9Z\H:V:1_N=2!S"ICZN^X:R!8NG2DE];Y:~53E4.9H18?V;B^9R40??*H_MVLJ3^];#_@MG^QI/+&D?Q"N'5G4^!-?
BMC^B8\>7J]>7OV8+&W@;QS81Y\NZ-LHLE\H48S)+\N68!<% MFPO(_@'E_P"";7!:"07#Q^%2-
/L(9+X6X_X65X1WRHP6BO\MDYB53M54R6 M&H-/G?X^~P(C_V_P#\$KUOQ)H.+!6T-FWQD;HM/9H?O_Q)KV7RUCAM=)
V(P\$S\$A/G4D==?PFX5K^G1P?;\$?K=M4H+&82JJ^L^KQ44T-BO_:ZOMKYB
M\>N+L^RU;QX6J>QC=S4<^C+Y=N95IN<^>|7RN^N+F6K2+9?B!
MXBOTLX_\$0U^4KNWM#Q%\$(X03;GF2V\CN(U6)8I,&OIQ/V8OYDO!_ [3_P-M/#OQ#|^*WD-I^K5G=-:C^ZT76-(@-O;ZA-IRND.M1BY
D84I(V+&85-H/Y)Q_MGP)FO""25=:2IB;\$JBC#^|L6S)3C=QCRJ\5=/[7V=))Gf=P%XEY-Q_AJ<^!_M?
+L8DXSP\$9N49QLTHMQ5M^S4K_2PO^50LBIYQ+&0N5WY^Z M&_8^!0W2>3CDR?:7(950>(?\$MYXD)+:
M7;ZGX>|4ZM1+K5KX5NM:LK=9?#GV?];&K+7:ZET7Q62W9JOF>6MK_MX/UCQGIMHUT+&F7%N;|5?>J>7;^6TKG;2Q9H7N%T-
MU/4;<|O/81G*[@_-RC;9/WG*_!O\PEPE+%9_MUG#P\I6VQ M/.H_*;7U>,\$|OFC=-V:2E9WYO\FW_X_P#@M5^QK<7*?|B%-6:Y-
QC(>4#C(R1RRD-+!O_!\$Q_VX!!):#X07R(8)723_A9O@YI7_M8\$K(K-;2;DL-
JG/O;P0)/\$!|O\6GPB62U\06UH20D6IDMOB\87;.57JO_".ZD!N/D38X/!(&<|&3JLG^=9^MP_!8?CHHOQ_TSP?XM\27!5M-X22[M=0\8>
(XQ)?EXVT^YF"+JAM9)7!_85-M6.ONLK*RRARD_P^HH_ ^%&6W^#WQ)250]RO@fQNX5D\$@M]@U22+&(I#8^6RJ
M>8V""0Q)G_YCQCP5-J9G>64^CZL7,3-.G5YJKQIDFCH_LMMW9_EF_M%;>|X_~=%|V.6.1I(Q)D48B8G;;MKEEP2SB16E_KC_
_#>_P"(G@_P_M\'=/N>O9+6YM?A\|01>)^IUI>-(WQ)\S##VMM.TH**68;IRV_=(P,W\CMWQ0+2?\$6_382SZ^X;Q^&NU3G2^;
%VD99E4\6!!Y9U*>J_ \$M?#,%5TK*W6=I(8=L?@_QS= M;GGM)KZ\5;RV2^8K1(SAU9E_8;I^C%QX/<_P#!:A_8V@= _OQ\$N&1JF&P
MU^>)P)4%@5&@DJ]5W-DB=-!^9_X^=\$^!W\1GQ-NC-HUYKVLLT7FJ+OQ;Q_Q_M^XMHM/E8_!17JX)+E(F.YJXF+HYT_<
>D>C)^P#^V3J+S_N_AG/O@D,D7Q_M^H0T95^1P=^E)W>8P!^;7+V;@EVWGYK3(>\$<.G3K<1^UG=)3EB\\$_V\!S
M2JR^OJHWOJ\56\1\QUXWQ-I8?A3V^1-C)N^S^5HM1J9OF=VF^Z;U/HW\ MG_!6G\G#QO>C3K+XDZBUV8#(T(^&_P_OHE<-
=6UBBJ\H\W;PP,EX@^J6)+QE< MQ^J_H^\$?B#X^!?:=J0A2J;4;&9\^|SH^ZL6D.GS;7>3=V;AF5@;C_"O0B\!^C#^!A5!>7>K>&
{3{7:6EM=:5XKAO+RZU.^LI=3_MM\O\+N\|O):T@O9RRP^4)H(^YC32J+W\5_84_X^4_%|JECQ-8W=YK\$60>\$|_M9L;CP?
#|XQO/7B.4W>N^~#^B+49(I'3/\$\$+)>0PZ+>PP7,EJ\#P23P2)=2_M7RK=^5G/@M2E@:N-R#^X\IV\$XRG3A^AB/W<5*2\HI-.7(HV6G-
&Z3DK^GD?_MT@;_/_/E_\$N44\|?DC&L-?#IRFN>\$8K\$Q=1PA/FAS734E;H?Z3Z?:F=M7B3R2LAW\+2+^~@8E")L-MR<+D\$^
_WHPO@_IMU_5B<+5&^T4X^88;<MV=Q|^~?QG/V_ ^KX=V?Q\)+W^7F2DKJWB32K6+3M0TZ-AH6L76DR;K75(6N_MDD,D!W2%##
{6W1(ZN@FJV@16;#&G@MP00\QR.O.C.=IQ@K#C_/G;^?ZE^O1K_MFJ.(A\&MAZM6E.D\H^D)^;FGK=J6>MN;F5DJ9?
Tf\0Q%'%018C^S5;#XBDJD^ML6G%:0?+|K<7=3YKKJ;N6BBBD= 4444-%-%-%!14#;|^G<-K_-N0%W1_~J
MV_NGYLY.T@L^!B@EU^O36RNU=^OYZ8.?HWK^V\CYEN-M%04E4_>)M^!-FY!&&+;(K#;0K;LQB,D;|/ @2YC2>;3XPSM;1^8f.C"14E5)
M%_Y9IP;6+^Y15\L8^!&:#|C/^E7_!3CX8_L_~^M9+V^K6C_ \$F34)?^DVE M:OX2!:_C86D_BGX:OXHT#R-3T-7^);B6712US_
&BT^M%)_DRVJS;-8=> M69;B\ZQ5^Y?0JU.9.2BN2G^JJ=)M<|^*%FTIN&G-&3NMF^F9\FV R#_UWO-K56-ERJL_P40_X*?</p></div>

```
%7C7P1K=O?I;M+XXN;J;PO_9NJ>.&/&-I6;-JKGP[U?Q+H.RZT..Q0++?#JS7!OS!;QRR1SR6_ML326A?M-M?M7?WJK'XDZSX^=7L-
CJHJZ-%72-N_$D@VUSX8!%5-MX326RTS7M8U>6*>RTXRWTHIE3S+B:XEC,$(-VYWX+Q+BC^TMXU;XB?
M$6XBAO=-3PVLFF;f&MR;)9S^&/#F^$+66ULJXL=+$MW-)8LCESL8K"HV%AM9OE5=(0F)48V7fB)
M^":X6PM+U5&f6A"IBJfTH.C4FH5*L/97YG:7-%1YU;X;WOR?P-XG^*V-M;XWS.K@<-
)-V72f3fT^..JK1Y&X1E.HDE*7*E+W+=N3:2LE%A@2fD>#=#fG1
M(YC(%C'FHJLZ&)8$VJ948>6FT*5PC(SVUP.UWGW2P!XP(4MFX3<@5U;M-U&67(+^3@J
KQJ@$@$J0=PH^F@B1&E^1;2G+EB^EC7!*@AB-FPKCW-S;650-H'DFZO95BM-f>4J+YLDDB8;,@6%02S1^6RVOZ^4A&
MO%#XNIR4L)>S:JV^LTXVO=-95Df6HZfNWX3H3fJU%AX+VE>?LZ:BY5-%-MRDGfE97fLVfDTK6%B2f)=;0?%)?
W<..G6@CX62_NYMBM^VQ$1!)(R-REA^N-MTY=#NfGf!@_F/_,$9f$Gf1?8GQ?^*MOXFTKP=-#6TMf!->_A+_$VJ^
M^5OIGV>32M8TfGfKY0);2fKf5YL<f8$513f1D2fTSfO)fP#f!<^<fF@M_-fXQVWB#3f!fQ%KPTf:##fE!W>_fOX@+f?
$fJUL;6fJfU30==U.*XM=G-Y-MO@fFE6WN+430QVWfJK7A?PHHWA32(-f.Z=8Z7fH;B;f.;RLf+;f/fJ7M-Mf2SMXE2;=Y)56*-V<-+
(^fMZ?@WB;Xf_5)RRR(-L(555G3Q%3GfHG.G>G.7M+%0Y>.;3=ES-DQNI7YfZGf'OfF>+EALJS^+fT98>C6CAY4&E5=1fJD>2fYUf#-(f^
f/@X^fL/fO@32X4fLK.ZUF;fNfJfT.#45_-M04-M)=2NT>72-TNfQK=-2,5CCBC;Y$;fHD=3(GN$-N805f;84DRG#fRJQ(#8S#D^*#MC'R@9#
<42USf1.Z+C)7^H3Cf!@JIA#X8C+fE2;f^Z7X5-&fJ8G$XB6)MK5^K.3E4GfWN:3?=-+1fJfTfOMMf!PfAL+A*
<*>$HEAZ480fTfZS2-MZ/f1.OfVf.fM?f17fDVVK16MVfOVND^BM0D^M(C%R50AN0f=N3@fEDD^2fRfX$^f^7.fD
#&>f+XIA$#N7fW&2N_C&SY:OCMG^fML;fEKP;WD3fIOM#+=78SY:Y7RYG7#MY;fONf.f@;%^4A^=.<9)P0/0<@B;9-MfP;$fJfJfZ_U?
HQ00fM^WX5)U8M-Z2GR..CL<fE&fJ;MWC;WfWfJL7A^U6_MG*fW#XB22_DY+fJ4;6>^EGfEK15F_@fF_PfD?X@3?
#3XUZ5X@MW5&GLTTP>fMEW(H&H;Cf;f_68BGW;fP7<@<9D$@YK^fPPOK$;K:382fV_S;fV8@0W_TM6fV.9QfWfR&?@D%23R?
fZfIJO_N^US2;A;fM#fJCR;f@DH=2-2Mf>3&BL00F.M0fLH;3"G^G^fJfB^X@f1_KXfV&NAUf^*f!f)
(WfEG>#P;K^XfX764fJYU;fF;#@Yf.f4f3#%04f9R3=2fN;f1>fJf=TEfJB0;fY0(M-6)f5P5YXQ^Z7fOE5QGDY(WVU4+A5^_P^R%
SDY7"@f$DGYL^ZfGG;9&C^M@<#f+Y/X6;YB-82Qf!D+Gf.f0X/S7UC7Sf_-SP^0fC@C^CRPTfM%%6_4444-%?GU_P4J&?V8f;^4G-fJCP?
T3D?f!fJ@&3_Hf9^f!fL=fKfO-M+f_-060Sf_P^E@_XQAUGY0/^f!)?=7=fJf6f8?f!)N6S@KSN+;f+GW>3+f7M#?f!R4&2?fJc3?f!
fZfOS7fJCPN)P#DGHGfMfJN?G^BC6#fXf_$Q;D#RVRfNPHVf;H=P#fI7fO?fNfHfOf=fUQC_B^OQ<fMH6f_XMSf^CNRfLEOFZ
GfYf10W77f0^fKfC^fV^f/-$GUH#^M<fNfIB8-fJ3DX>fZRC=fJYf(09$?R_M^K=^RWLOfQ;O)SNf!A.BHf;N^O+>^JEfGKH6?
XfXG^fLW9)P^KfS1997;2.MfHfP!AWN903_+f3^fF^R(QfH^M&^HSCH?f!#XK1>fBY^fTKX5fMfQfOj.D3);f+J-
K/3+fJQ^fJPN@OK>f!M4fTCF50fYfJfHfT^f1D=fJf6fRQfJfMfY=-P6;&?VN_-#56_P^f)Z&P&fJBGf9QNfV3fB0PPV7?NfZ?SfIJO^EOf
M@WES_P-6>#D((3ROCLVUP67f_HKfYf7fRL^AR>N=C^DOF7GfJDXN52EX80=&MM4fI3fYfBZZGfH2fJ$S^Uf147RMQ?NfJ-GK=-"
P5Ef*&)f78X?&0AB(fM@^>fM<6fJm?f)RDU^fV7>fJc>ZC:*5S^fVfP^fLZ?fPC#$VD>?#A.fT.KW^A;PL6_M<fE!f..0UOH<>5,<f.<
Y#f+90fV@fSPGY3fI&f_AfJ^5_-M8R^0%f%@fJf>XfI;f1YfF4W7>1&%fJfHfW$;fV6&4Y=@Q+>R6f(WfG<MfZ2fJ;
<#fJX^f7NQE!Q^f!)W$;$fFW;R-Cf!f_Y_X^fH7fJ^KB<5fSDYfJfVfP5_MGfMN5fJ4K=;fFM>6RBKNf5U=9MM96_MEL56QM>fVB
fVfV@V@B@A5^5.3RBD4fVBMfYfC_P^M#EIOB;f!_O^f#fOP3;&fTfCfN^fM?Q>;>0$/%fMV<fJYAfYf?>?
H7A90<^>f)3C4E^VfJ3#WDU)R5ZR5<^>5^9-JM53DKfIOX7^4^SE+@+@%5)QfL<f)1<6HM^X56K1UM(WC9-Kf)_V^SY7
MfJ5^fF^W47$A^f7Q290.0$fJfL_&fJWD0MfTfD7W_@8M;0$6Y;f_B9_P^HfXf11_MYOfAB;HK^?#NA?>VCDZ-
9KU;SQR^58?/E7<%9D&RfL_RfOV;P?fAfP@P4E_MAf_BUAE7+f?Wf;f@9fDRE@?8^29AQY_G^f9fJ^#AfD3f^Q7)SX:T0_MALfBf1_9-
MADPfUGG_QOER=S;fI<fHfL_MfI<@9Yf.FW!U+f4J6E)f4ZVW+K=MX33LDf!fCX#Z;fC2:YE=-fIK=-fHOFN=_&?-(fL_Mf1<fL-
f-&f&f0QAfJ^f..V6#fY6W?f!JM^8f.46CEQHfHfB<f54N952_&fJ6_MW8P)K5@G;fU/f4=-R?6XAMfYf5=8PK^SPH^5PQ8NP^XE_N?f#_-
(f+K#f!$M7Q4PfL_$S^f!+&#?Q^XY:3EN+8Y:7YfPG?MY;WDZE_GGW0S=ZQfN?fJfUL=S_MUAN.<>2-7?UVGfF??S?
^f)AfSX&fUfAC;f)-7^fTfJc=fW+6Z_M;V6f7YfH(f*EQGEM-f3C_9>&K33T4YSQN:60>W)fJUN9;7_T.f?^>Of%P)?X
M06_B^#P(M6U(f7FE22fJFA>#fD_ZQf+>fER@_Oa;SFA22fEGB4RON;TCR?fMfMG^V?
K%fI/PH^>fDVWD60@fP?;fDB;6Cf;f%&24@fLC9CTH+EHfT4$D;fG8;G5_MR)ODf_@G0_-fES_fWADGUY^fGP^&8??SV!&fN4L?
WN^&MBfMESfLCLVfT-Yf3UfUfJN93<>f9KD73#Q%<fH+>fLfO^C22^XfECU#fJWY
M4&XD+fIRf1DKfL_S)fHfNfYfL05W^AON?fMf^90VP4CfHfWBT2PHZ_PfL^f#&*M&-9%Xf!<fP8HTf$SfJ88f+VP#PfKQA4QF%5>#fVZE/V
ML%*fLDDGfN-Vf;f1FW>39;fFf1YG^fAJKfY;C>25.Gf-QMAY2NfG:=fTfMfFK)-fH-f^6QJEfJ_A^QfXB%f(fJfT^f!1+8WT+fE;fT01?;=
$f@NKf1T83R)fM^*KfF^189fQ8RQ9Q2L+K_2R_P^f..OQ8UKXfL_L_V=-K45@+KPTf^fARV-H+fJ^MH_M_A$X3U_2W#WUQf$CS237SL$Q&*
K^N42L2TR^f^4XfF?QEf4@f;CQCXLV8(4_M^fJ;Q;M@f!f8;f078;f1fJG6?f1_X(SEG_9fA2)f)V7Q5XfA(+?P?P^fMV3NfYMR^
G<0)f)=fGfJ^fV+HfKAC)96@ZfJ;fZDE>=G6f02fH^fI;fDO9T;S=f7L9f+ET5KfZfL_6fJYCA6fC^M^N;NfUPOC^MF25_Z29S+fF^f!1$?
f9&>fL+G.fI^fFR@^4D^_fV7QfL;fH^2WWVfS^f!fMf!fMLN6%f^R7^VG;U;f+C>UM;fSLW9NR>LCfZ2^fJcP5^fYV_MY(f/<9fV9.fH&O
f^fW#<fHfO)fHfY;P;fMLGYfL_ZfJfM=6Z$)7OK;W;EMK:fU^fP^fY-SD+=W+ZA+fE_M^fJ+77SfHf_5GX<_P#f!fZ4K^R)58_H8R>#?2^C$L?
(f^BC6?<fI<f9S2DMZ6^fJfM0983WHfV=K.fI.2OI>^D;fI_P^>fJ2X_RMfL9.f!fNTDfHf8RK=-6>FE_7=fG^fMDEf!fV6_@KfJ?
P=->fJ77A0fBfGf!<fKBfI
```

055L7;^Y_5^%GX9T9QE5IRCE5N)+E<5.6&A:ZA)ZV; MN]/>=G*]C(4X)3K>;&(I3)G4CBMK.;\OZ-MM\A-ADXS):KB<^#J\N4[Y-WA? PH-H0\91?#>8PF?F50[A^X.(DM/V4_@C97-MMHJ=IX1T/I1-W45W#(?^OA-"DUNZM&V^/PXDLJ57JG1N^"M;,*AA^F"@RJH-M%VIE&-HP<\$=O+QQC@8-ASM&-T=8(HC+@A&P\$A'S'(S#f.-C*1H^J>I^7;M^L-DNCF6/ITXM8S\$,*DURNI?F3FX-*R?+OS-JZ?+;S?JO? V3ETHU9RP.&E. MDN9/V:NY\BC&209MIVW4FTMKUM+2+O#FE7=J&D%J@BCM-M;.*2>0>1.0Q(%!1FJ?+&\$&QLF/_A ^P@MK^U1XB^7/3?B-X=P7L7_-(M?#*XC;-J&B08?V-87ES:Z[X>T.SN8J1@U^*GLVAVZ>{G33J5BQ<2D@!(?IS-M/VB;E-&-_QB0AE3_-&MPK@.7'D:!=LV/+A4HP.2@#I@F-H@NZ\A-S?VMKJ;G\1?M*?&.^WM<'4-4@=6829+&SC0D^Y4LN-H-3@|S\LR@)Y7J3X(910Q.9-MYEF6)@JLL-&40>O)TY4Y^9G:3>9!-MY:1? W5_#JF-X1?^KPJ8^Q^O^_A#0;V#2K7I;W>K^/#+7LD8GDN(S/+9Z#8-M1-.DK;0\42_*X5AE?P0-P"#>NST3PJ|\$XJ4N2(G^N^\$WAB* |D6?^CP^?J?M9(V>+V9I^F2WJUG@.(X\L@A?Z-3XZ\J47J5^_*#6%T=Y!Q@L+;#=#P>X((^M4I/G/%// M\KX2P-.PI^SQ^A>I4YJSOS\W\>15#F7+?W%W;3;NJO;PAX9D5J)X4-M-B49^T1+HFF%^"O3YE%G^J4D88GE2<..H3Y_-L-8D^#6J10P\UGI=9T^"#1[N-M#3/\$]QJ|SX8T;PAHJ)?ZKH;Z:H>ZU/PSJ^EB (KP2|HO*D|9Y^BA4^L9?/MAX^LLL|B^T;V;X20A;5AZ&;A4C*#@JD4EOLX30I>JWM?3EL-M? J>+PN6XRA^AC*^>GAW3JQ=-.K3A:4FGJUE^;EJ|75W=1LE8-P-R#J|N+JFV;MJE|X|>//A3)? 7&A>+J0LJ^TF^UBJT;^U8R2:3;WLTKR-18V%HD\9D-V:WL8-M83@-[Y_-8_-((?M>Z[X^^(C#X;Q>07&BZ/X^|&-.HK7L7B34+R2YU;X M@8G\$CVJZ^G1H^7;7+D8Q@4GAL@AXO\X_-#TNR^+W60:<&NM?Z[X>2^BN7;*M-"T%OX;L6QA;5+@E6^=(E-YPI-R-G_- \$Y/\$5QX_-A\36KJD6L>*OAOI-M|MY=P*#@|9VC|2((U9L;CCS@T1^PG@-ULW^BOPJG5S^FHXNGAJ-92G|S<90 M7.VT|E/..6MK/W;VMS?Q+AHRX)|694|\$DL|7Q>)KT;-INC34JKG3A^;G^JGR-MPKRE)+H-O- U3J+RQY|Z+X8J4ZZZ^8M%T+5=6C8H|HFL+.;XVRQQ^SM@#\$>^M(@KN;|70X?YT\A-P5E-.8|2-M-2M-^J(U^ZAC\Z\X@TCQ)H4>G? V|J;R-MJ+06\$JO|+.;K>W\4=LT61RH;I0E6-OR_-4|2)I?|Q5U%JL;R-G-MSXB|QX@0S|0JOH&HE% B00%RH.|^YR< U-E^_-5+SQ#^00\$;K7A;AO=-TQU-ME)EW^"8VZK|TPED55^+;1MP.G_-/S|L-5Q>-S+PG.CA^L(4YN^*7-[15-M4VNG04XJ7?2JOAE^G? 20S[|0P61YIAZKAJ9C5Q>FI?&HPIPY+;R<<0V^S-M3LNJ-3#-(?;L367|87QP|260B;M;Z7X\A>_%^BT34?^MHDRKXYT|2;F-M*:#7J (UA9+5H)6+V\5\$27+2\$%G;E^-OK^%?|;|PB^\$&D6^C^%-"FC7T-NES%MY^L>?^#37;1W%ZJZ=TVG^|/5FCD;C>6- JX(#,26-FU-P"#;KPF+>V\0<6-MA1CJOP=-;G;K80^8/B+92%6Q&LO#(-ID;R=U5^C?_6^);/M4^C@@@G)/0^\$+ MDD9ZCJ3QNSB3YSQ;S|&XCBG%X30S&8N!4G&4:3?Q^"FTFGRJ^O%WL|-6LFFS|_M#P-X7RS\|8;OJM^ZUB:3DK2YXM-.3330S&1X^+N5M-MAGP^A&X|8|T|XV|;^N/JE-Y0_-(<<-S^N-"KX=>((;UO?!A.X;D|2O=J%FG?117-VYKZ_#FF-L&?_?2/M-QXJL-(DL=;NXJ-B;ST;P;V2MHDUI\$Q=J6FMH|+73;GW%#W.3+M|Y| <(&E^\$Q^1U995|)^6PHX|/A|41L^6^0X8G^&G/#;2I)|&Z^4R5W?ZS-MEXP#_-1YQP=H.%RISE|Y;R#X|9P@^(!-&3X&|89P;9A PGFI8RP3/4|_M/;^6F<2=E/%UPQ^AB-U6K|F|^E2JYB?&J|/HJU^5^R;M=-*-(>69?E6-M%\$S-Y=A.6&^L4:E;\$2C%N53EG;2\7R^HJM_-J+J-DS_+&\$^-W-QXYU&|XH5^-.M%\$X=-Y%7;Q)TFQ#N^N^L6^~^78^LC;Q|W-7W7^JIG-!!?_9;~7Q9|6/B/QA8-MOK%U=^O&5QB|L/#>H0K-HWQ(-6JNZC5M-U^8L(A)&TK^R5UB^H|_-&G^M73XH-CXBZJ%X)|.^."H&?;T6PW<-3U!H2I5P#>#PF+1JL<10A4HSA-LJ|L6 M((+1W;7M51)"@IDO_-(^UW(|?@;7G#%)YGLZ5P20/F+RJC17|MB5^*(JN|JLW->O37;322ML00?31-P|UTL^A.*Y84^2CU7LX; |.OW;7ZWMO9-M)WO|0?M0-L6_/_X>_2-2V6^DKIDEYXAM+KP|H7A.TO)+ZS|+^(-\$M+>-M6YU^POJ? ^@K#JTFVU0LDLT<#?;!\$D=S-G_?M/?^\$;X&?%|40AK;)+I&BZ#-MX/U.TN=1GL+S46O=8YGA7BINA2P.E M)DWE^FG6CJQ)OEOUOS.V>VC_-)E^DAE66T^"@V_#^XN^_@;EM8N+M-N2ZG^_/@-"W-DGN+V?3Y(HH0\$4L;>3:RW(\$JL793)|M-K\$&<" <<<E^&""003^>?)J^"GA<+;Z104^6PFQ+227O5^+4MD|?SLT|5H|FWW;/TSP6Q=?%|X^K7G|2?UG\$3UORQ5^|S|+|JVTEHHHK|/ MU<****"F.(%SPWRL24^*E;G<(((<\$L/E&W;H20HAEOH\$);^9CM;Y0-ML|VY|JU<=4?4WB<=>9#RQ&)(3:3X4-I^@PAEW&C)|TBOE-NZ,KOM!M15Y>Z-MDUJ|NE;|5JZO9:H;46E+2^N|MI^R|Z|^HJ%*A)%50F(ED&-HB6,*V0&A0-M@R|6^1&0J PCQNMIJW)+=+H97BNE^:UO-S+;L-D^\$K8C\$12J004PV\$YK5|M56=Y1A0J|5G92ER4U)VB|1LK+|NO|_@J_-%/##/|/_@G6? #7Aj;2+OQM-MJ5J)X.EA|0>_%&=J^;KXM^%.K>*-&G@O=|OM#1+LW%QI(23|4UK90>8DT<4U-ML|VF?P7?%?XU>-COXRUX3XB?;\$? 4^==UJVT:~|TZNJ|8N^#M9|%/AVP|^Z?/8-MPZQ=M<17\$NE:1!|NOVN6X^SFRM+@L/ZP?VA?V&BWXY|ZQXF^*C)M^<30Z3+<06GB? 0;VU@DT7PA927-M|?)J8@D8LS^QA4ML^MLB^NU<|&A-P|_1/5-P#GGK4GVI=M^76V%M;|=PR2>(?#&\$&C)WW+%(XTB|C;A;? N9%2-00A4_8-D;Q)^SM|6#-M6060AN?1;);RXU#1;|^=K&F2)^<:XD/V99)XW1|O>|0_-D6W0#S2AB=K3|;6-M(PE/F5? \$*O5HWKU70J1G2>JYH-0;Y6IR;NW&4M%9.*E^FH8K-XJTL@-:(8-MM2C%^J'G=6R6EG&4^>RU3NDWR^|XS)<0VDEO|K2RW=|8V? GJV|ME|BP-M|@<B58:1HX_-EK&^;4\$+/_03-P-\$J|_@D?XG^/FM;^8-BE8:UIGA9X-M=0N|FV/>^SQRZ|X^>=AIK6^AG:OH^N7L=G-;)=BX8^0UPRD6M-QQ);M_3-2^_2^-(EQXDM^WQR^%O^OXGTRXNGUNT.EZ^XL^>I:J^O|KXF16^E-M(FG7?A?6K^>7>E:LVH% ||=CSQV|V^M#%LJ>WA#P;H7P-T^V^/_&+M+Q-MM^O)H46-G:0%-?TJY=;186EC;KOGD;7Y(HJQ?+>AEDDB_-"/\$OQ6@^?)HE2 MR3B^91-Y7&5KQ;33NVWHE-6GA#X+2Q\$J\$/\$%OA|TX5*\$M;52EAU7JHX5(N^MHRA^"OSQOHE962C|> M|^AJR|+;|9I9;)937MQ;A-M;RMY4GU&Z:^NL0Z?HJM;(CW\$DKLL-K<*)7);+1=D;JXPA?;F^0\$%4JPQC-MCRT* D;3RI&|O+@^0MJD)C^AG;S9S\$C\$%70%B/(W^05VJ^V\$;5LE_-06V-MN9-7WAERN%;>5V#C|QED-3D8# &#&OE-SA4;KU)8JLJE7\$2G^4I2=>Z/JZ^A23P^A&C0I0C3C^4>6;4K0E-R5DKM^@|Y^"0JH^RE2-M&9C&\$51L7I-Z>461L^PPIXQL 7Y^*J0CVR;MD84^%VL-JHR-5<=P.GDJZ6T;6W623Z8Y8#^@#<=\$VX;XGMZBR0XD#K_(-P^"-+ASDX|);?&MPSZ|J;D-3A)J^G& |="K4;OR6N|L/_L%U^WI+W590I|=05%)V#;^T;^<+V5-M>^_G)CZ\$CN0-0PQA?/(C#X;B|4?#;Q^HY^

MS=7+6^C>\$=0M08)+686%HH(JJM)BY_U7E#1^JG_1,OBCHM=G+K_@/X;7.E:8(KW0=/M3/JGBRROI?M#U#26U
NOY^R6]-.H#Q(&?_PT_M"3QSJ_P%+^E>,1%TBU7X8ZS?+=?"f5<6XOH+6YM)/+_+DLfBX^,R_JG=Q
MDP>=BOZVX9Q6&XW/L7EE64^F)IX:O"G24HSJTZU&M_/^Nw>+C3E)65W%6-M22BI?PIQGEV)V?S\$19QJH&
QV.P>BW""5.G(&=:A3Q\$<KW>>O*G5BK-MIF MD[OXO]6FSNE-MJ^X^PW2Q7+2;"CE)/+;RRNZ-OF&0WS>H3&1_S_P7_-<
MNOC/^TIX3&6\$UHJEX(A^<?@K54M,36-ACQCIDI0E:H7<H=RA=5;9H(FMP,M^RCYL/Z;?Gf;A_3/^"9NH_-&4710U3PKI&?_VLWY.C>
(FMDQ;ZVL^EVQQ2 MC49H@<f/"04?_YD;_+/_/USI3/B-13O'-PYN1K?BWQ;KU@ZQWRQE-4O)
M+MBL=^;BXM@iC;,\$1B/Q^)=05^0^;.&HX;/,SQN/13I++5.E3=2'(HRA3DJU_M1W2TE0D[VJWF>NTON_-OC2CBIARG*M_M9N@)/4--
N+RZPML65;#H50#YDW#Y/f^-.TR/3-/M+^"T&C;2VAMK97CC11%;_MJ@VK-BQX(CCA0\$#J8'E-Sf\\$_OV>;OX8?+QWxKU>RVR?
\$2X^<\$/C/IY-M+K2;U157PEK4,LZ"SM?M-KQUKRE!PC&4:3E/313]BJD>:WQ:-IMN=8!""4&YM MK-.ORJPVY*CR3DKC@X!;+<#;..W?
<8PICOJP>..PP>PQA:JLA"1M4W%6-M&4.T8V=Q=048PI/7=-V1_#UY52_5(f;?N#C^A3I
#_-FK)P<_JHPIE+^;_J@DK65[VA%7W09PI+7_P f\$?C_-P6RX_8L^_Y M_-#1&?&?+<?)"TKDYA[-3UX_-B!_9A
_SNA\$)=4%R65""YC;_Y/W7W,@!L!_M6W!<<1_C(+Q\$1?Z)?!_P6S1C^Q_+<<#_A3^C,DE&R?)"TKG^HH!7fY'S,_%M4D,F-Z?YVfI.1_-Y9\$_-
AA&fUA\$#f5_"A"48%>"03&1^X_KP94%P?BZ, MXRE!S&VJT4.52A6E+6VD8QDW9K3>S=S^<f%?)"J68%Q:"
MC&QOMMN2;_BVDW"67^A!_P0!+_+<B1)47X=-!0KYD80,1/HY1(5**N MX!-NXJI+!)R8P6/f/K%M8SRBjA4,4Y&?_*P?BG_P0-MJ19?
V8K)EQM\$*_SX**MM7Y=VW2?>W^E!M^G<M6CU@FTUJHOJf).S>?<84^H8H_O-/M(R^08!3Y!_+!>?0D!0f)HLX3AC#02KD-
&HSC81C0#*_#_!AD>6<3_!MODV<#(WH#G!!\$9;)W)AFQ^C@A3@X_"fL_3^"L4.X.&EV[[HMO7JEK]=>*_fY)RTLW3NjNK
M20T;00>5V[f^]AZAH.A:KBUU/1)+OD96CjZTRUF5TD[L2(1+^E^J_OD(A,>MXX,?^C?R;-+!>Sj@OP1H^FZ7!>0!&KV.J>?#^Q_1
B3JUG.S^%M,T2;4M-MWPTN;^VN+&fT.V>f7>G0?8KK9#%J\$EW^&9&%U;EC);?UR311L!fWf/WQADM,0_M1LFZ33-(-0.9+Y
RF&A1)049J,T2;4W&7+T:2B-MK6M&5f/F?_!GA?#QS>?#_B3!_+&FW,MAK7A/Q-I^OF&VDNH+2XO!&ZL!f
M\$7!>J>YN(X9^"N8;JWN(EDBGCN+5B3?ZG^!_#QS>?>3JCGJG7=1D2;4f MSX^"74KYU^UH\$)=A;ZBTA1fUYYG(%GC>)5.Z(YFB*
(+,_HU^8/XBU62W2,MP6^I2-!1TPOF2f6_#404_N0"\$6!MV2#fY9:R_TB0^"5Y/!<QGf\$HY/*C^M!P8\$.-fB80&6]FW=8B*/D1C
7:#&\$fJU_VJ_M.UG^X7NO1>fH>f=Z7S4N9J]f5f2T;MOE:~S;XDFK72]fZ_P""C7R_L_-M7C;S_P,Y?%>7>9^A4C_GU0\$5QD#;&
M1L)41&/=;_YEWQ,*GXE?\$, \$C_A)KJ?+!>^>3D1^8_Y""?+Y6%8MEA_MIH_!%%"WfB/JfP!>R7!_!%G<
A!VKX;D9LGRV(QPEF&_!A;JT7FV7^9_M9!3XjWQ^<(SY/IGQ3?_fF953DB2;@D0#H4E9=BJGf@!!&(PVG1X#W6!SGI&
M)G(MHJH1P*_*VJDN>T9-D/1+!>f+76>Y!+^H2=10?6)Q\$59WNG;XZ6-MTE=K_P04CS^RUX>*_@LS_SjGDD^N2DWQ7)8?<GSJP8
C!+<fHfRV<^&^U_2C_MjNFYE^8X_<>(1B1^@f5)N4HN^PG=8+LT4>S80\$=RUOL^ELIE7.S_-G_M(OCR^V6_#DCIR?
WjGORS@Y)\$GQ8RS(H-3^X+&J_-@fW5\$V ML^fLH_M(6<+<(JU\$?B7;QHS+&3)-X5O5BW>9""@W1.KL73#*%+<(Z^UI^_!1U
MHQX_Q46TfTfP3;7^M_-Jf&OLfZ^<=J?WOA13J>&67^EK;_L8FHK;7\$H7<M;JZW=NKO_F\$?3SKGXT?&f=295!..Q+*
fC9G\$MX2!A_0=IMR)F/=L!_ME^6/L0!_7!_P;_#PG!_#C)D!>fLL_f0/f\$>J-M#G@*N\$961PVLRL!S+&E;
M67fWf[250+FW0^f1.DM&=fM?NNV10<_<f;FP.6J;8!W:MA\$*_VV;NfN+2>GO?S!X0!&6<M14K2S.-+9HXSG91!_+>MYG?
V=^fNK2FDfJschf7!K0*_=-ZGfR4OWBFX>fGR6YfNZC&GS_M_-N;_NOKf768f?7PHR>0>?FP/fX.R!@%fQfC35B/^&+X_*+f;GXF?
#VS^4M;?&_XfJ%<%Y-^&#>@4L6#(f^MYQfH^fH!_)(C?9_T_P@fWXTRf72]GfJ9G)-W_-V7_@GOIB7Wf8Wf.R_7MOCWf(&P-OW
Mf5MA4fJG5LXPG?#QC9/33NO+f23JYN7<5_P%_U0?MK_M#*JL_M2OQ3UO<-K!A9<&P3\$!5E.23%Rf7""+!<R7_!M8/^&^_!X;_<
)%3JGT?M%>BFMFVXI^fLG.UWT/S?>48>C3E%M_-f/f.-D94J_fJ6N_@f2=L+M;_QD=%)8Xf5L^MP,8P,fIM+10^J
MZTf17A&&=RfJZX^8>00<,<^fX!(P!L_D""DZ?&3;fH-Z+>=U300:UKZW>G7_M6S_NZf56fWf22AUMf!R>BLW:Uj(OOS6NY?_Wf7DC?<
*_OQPL_-?+>XBA3_MM0G^&fHJX_D(C)C!+<3XO!>_BQS_-fB?33AP57UL2^_Q6!&6,fF>_M\$@&2>=>?KNC_BGQ67(P>f
M>M@fJ,YW""N;8.S^<f_-@AE^SM&?C3!#M)f3V4UYK47PSV:E?>5X?FB2:~MQ)K-NICEU3PJ#S;D@0-fAPH!>_<fW<_@GO!
LfW#9.CREU99^HT;P^N<M84)SX+&5P,\$#CC!<fST>f%>AS*;
fQV58f(f4DJEZ7A!>#_#%&=fY5F65<1/fTf4Y)_%A56Z4)UE!QcJ"P8#D9^R"-M_-&fTNZ_-M)KXD>2V^?8_B;Q5L;GKSJ_-<fT;BN!G_-<fT?
T_X)_?L!1.fCp6=^P%<f?0_-M^T=6_T_Y!&(<\$G!>?>#>f%>fM8MUSU^f7RGXO!)5N64>)...6-J<964HQ&C5Wf?ZMZR5UfN5WT/8_X@1QLf_-
M_%f10IR=U^E=-RMS64L^6LFFV_S0!SPYfWBWXE>?B7<12>+fJ2N=1N;X_M^WHUS>G2fHBSf6+ZA^M9;7=^fT4_X7M+&B)f&f(JS6-
PMU_M;LCVOA^UE4K.NYBLNWfSNf10fJf9XW9)+<7EU#*E^ZS0E0N^>,(7M-2E^fT_MLXQ6ZW2O)V1.7_1XSG#90A#0B&@&Q@Hf1?
#>fX^<K.T^>2>YSM;fU?Yg7B@O>:Mf?BY^EE;#3W""PIDL3:1(X9)V^<fL_-P^MZ%0\$/@Yf5PL8fV?X9:C)D8#*OQBP;
f"SG<fS!#&U0"=Wj,4*@W,^5R+^&MZ5_#?>QA!XSU_?&fEESA_Y@_P#@W)U>VD^<6BfH>fLOA?2SQF:0(HD^<
MNJ#S^K(f?/E@fJNR9Z1@f3XK1^RD_LZ;3E6PYZKEA\$V<f+>3V)R_XjXD_M2:HfVfY72fIMPZ^>Z6>RUMO^f^\$50!47+
M&f;HXE^HfM.K^K7E_M^fTKM/WDU1J=;%_P9_XZ?>?P3P_R&f.QYSUSSEB89+V=WREAPN@>?<
G:6QX5%0f54AEQD=2>2(QGKDD>3R23EW_/4;0&/RN_%;((&2!M4AQW^4>F<@X/QJ37>_f6;5f_#S+750f:fU7KL?
HT%HK%)^ZLUHf4K;WTL_M^SA+4;_KfGB3EDP>K<\$>0,1<+D8.7SEO^_CR^BS_Q_X!_XH7QB,8X_MY!_EP3LZ^f7(f_-
"USB3V""3A);_&2F>NXX^6#_R/E^W2

